Emerging Challenges and Opportunities in Pharmaceutical Manufacturing and Distribution

Miriam Sarkis, Andrea Bernardi, Nilay Shah, Maria M. Papathanasiou

Processes · 2021 · 80 citations · 54 references

DOIFull text

Open access

Concepts

TL;DR

The increasing complexity of personalized drugs demands advanced manufacturing and distribution, prompting agile, reproducible processes integrated with digital tools for seamless communication across production and supply chains. The paper reviews how high‑specificity, sensitive therapeutics are reshaping industry paradigms, outlines recent research directions in manufacturing and supply‑chain design, discusses challenges and opportunities for small molecules and biologics, and highlights process systems engineering tools that support digitalized manufacturing and distribution. The authors survey recent research in manufacturing and supply‑chain design, examine challenges and opportunities for small molecules and biologics, and describe how process systems engineering provides decision‑making tools that support digitalized manufacturing and distribution.

Abstract

The rise of personalised and highly complex drug product profiles necessitates significant advancements in pharmaceutical manufacturing and distribution. Efforts to develop more agile, responsive, and reproducible manufacturing processes are being combined with the application of digital tools for seamless communication between process units, plants, and distribution nodes. In this paper, we discuss how novel therapeutics of high-specificity and sensitive nature are reshaping well-established paradigms in the pharmaceutical industry. We present an overview of recent research directions in pharmaceutical manufacturing and supply chain design and operations. We discuss topical challenges and opportunities related to small molecules and biologics, dividing the latter into patient- and non-specific. Lastly, we present the role of process systems engineering in generating decision-making tools to assist manufacturing and distribution strategies in the pharmaceutical sector and ultimately embrace the benefits of digitalised operations.

References

54